We produced an antiserum by immunizing rabbits with purified human megakaryocyte colony stimulating factor (Meg-CSF).
Introduction
The regulation of human megakaryocytopoiesis and thrombopoiesis is only partially understood. Recently, hematopoietic growth factors able to specifically stimulate megakaryocytopoiesis have been reported to be present in the plasma, serum, and urine of patients with hypomegakaryocytic thrombocytopenia (1) (2) (3) (4) . It has been suggested that at least two humoral factors, megakaryocyte colony stimulating factor (Meg-CSF)' and thrombopoietin (TPO), which exert their effect on different cellular targets, are important in the regulation of in vitro megakaryocytopoiesis (5) .
Meg-CSF appears to be distinct from TPO, a substance present in thrombocytopenic plasma, which is responsible for megakaryocyte polyploidization. The effect of TPO is quantitated by its ability to stimulate the incorporation of radioisotopes into newly synthesized platelets in recipient animals (6) . Meg-CSF influences megakaryocytopoiesis by stimulating the differentiation and proliferation of the colony forming unit-megakaryocyte (CFU-M) (4, 7) . Thrombopoietic stimulatory factor (TSF) purified from human embryonic kidney cell conditioned medium, by contrast, does not alter CFU-M cloning efficiency, (7, 8) but accelerates the development ofsmall immature megakaryocytes into single, large, easily recognizable megakaryocytes. Vainchenker et al. (9) have reported that erythropoietin (EPO) promotes the formation of human megakaryocyte colonies, which suggests that EPO may also play a role in the regulation ofmegakaryocytopoiesis. This observation is of interest since it may provide experimental support for the clinical observation that active megakaryocytopoiesis and thrombopoiesis often accompany active erythropoiesis.
We have recently purified human Meg-CSF into homogeneity. Meg-CSF increases megakaryocyte colony formation in culture but is incapable of supporting erythroid or granulocytemacrophage colony formation. The available evidence suggests that the active molecule plays an important role in the regulation of human megakaryocytopoiesis. To further define the relationship between purified Meg-CSF, EPO, and TSF, we have succeeded in preparing a polyclonal IgG fraction against the purified human Meg-CSF. We report here an immunological analysis of a number of potential sources of Meg-CSF-like activity. In addition, we show that the anti-Meg-CSF IgG fraction (AM-IgG) reduces the ability of aplastic anemia serum (AAS) and purified Meg-CSF to enhance CFU-M cloning efficiency, confirming the pivotal role that this factor plays in the regulation of the early events occurring during human megakaryocytopoiesis.
Methods
Human subjects. Bone marrow aspirations were obtained from the posterior iliac crests of hematologically normal individuals. Human AB serum was obtained from normal volunteers while AAS was obtained from patients with severe bone marrow aplasia. Sera were stored at -20°C in aliquots before use. The bone marrow and serum specimens were gathered after informed consent was obtained according to the guidelines ofthe Indiana University Committee for Protection of Human Subjects. Source ofMeg-CSF. Meg-CSF was purified according to the method ofHoffman and co-workers (7) . In addition, the biologically active fraction obtained from affinity chromatography was further loaded onto a preparative sodium dodecyl sulfate (SDS)-polyacrylamide gel for electrophoresis to recover the 46,000-mol-wt protein and to assure its homogeneity. Recovery ofbiologically active factor from SDS-polyacrylamide gel electrophoresis (PAGE) gel. Samples (2 ml) of concentrated fractions obtained after wheat germ lectin sepharose CL-6B chromatography were run on slab gels (1.5 X 140 X 1 10 mm) with standard molecular weight markers. At the end of the run, the distance from the tracking dye to the top of the running gel was carefully measured. A strip of the gel was cut vertically for staining as a template and the other part was retained for measurement ofbiological activity. The unstained part ofthe gel was sliced horizontally in sections according to the position of bands on the stained gel. The gel slices were shaken overnight at4°C in 10 ml of 0.02 M sodium phosphate buffer, pH 7.2. The buffer solution was decanted and saved. This extraction step was repeated once and the gel slices were removed and discarded. These supernatants were combined and centrifuged to further remove gel particles and were dialyzed against double distilled water for 24 h with three changes of water, followed by ultrafiltration using an Amicon cell model 52 concentrator (Amicon Corp., Danvers, MA). They were then lyophilized and stored at -200C until reconstitution in alpha-media for use in the biological assay or for use as an immunogen. When comparing the unstained portion of the gel with the biologically assayed portion, we took gel swelling into account.
Protein (12) . Immunoelectrophoresis was carried out as described by Grabar and Williams (13) . Double-immunodiffusion experiments were performed by applying the technique of Ouchterlony (14) using immunoelectrofilms and double-diffusion plates (Kallestad Laboratories, Inc., Austin, TX).
Iodination of human Meg-CSF. A modification of the procedure described by Stanley (15) and Stagg (16) was used to iodinate Meg-CSF.
In brief, purified Meg-CSF (1 jig) was resuspended in 40 Ml of 0.1 M sodium phosphate, pH 7.6, containing 10% dimethyl sulfoxide and 100
Mg/ml of polythylene glycol 6000. 10 Mul of 1251I-Na containing 1 mCi were added, followed by 20 Ml of a solution of chloramine-T (1 mg/ml).
The mixture was incubated at 4°C for 5 min, and 20 ,l of both sodium metabisulfite (3 mg/ml) and KI (0.1 M) were added; then 500 Ml of BSA (10 mg/ml) was added. Iodinated Meg-CSF was separated from unbound 1251I by chromatography on 10-ml disposable columns of sephadex G-50 run in 0.01 M sodium phosphate buffer, pH 7.6, containing 0.1 M NaCl.
Immune precipitation ofradiolabeled Meg-CSF and Meg-CSF present in human serum. The purified Am-IgG fraction or a control normal rabbit IgG fraction was diluted in PBS to which either radiolabeled Meg-CSF, human AB serum, or AAS was added in a final volume 0.2 mi. These mixtures were incubated for 2 h at 37°C and then overnight at 4°C. 10 mg of protein A Sepharose swollen in PBS was added and the immune complexes were precipitated. This mixture was allowed to stand at 23°C for 2 h and was subsequently centrifuged at 8,000 g for 5 min in a microfuge (Model 59-A; Fisher Scientific Co., Pittsburgh, PA). The precipitates were washed three times with PBS and the complexes were eluted off with 10% SDS and 10% beta-mercaptoethanol at IOO°C for 5 min. The complexes were analyzed for radioactivity by using a gamma counter (Model 5500; Beckman Instruments, Inc., Fullerton, CA) and were analyzed by SDS-PAGE by the method of Laemmli (1 1). After the completion of electrophoresis, the radiolabeled Meg-CSF SDS-PAGE gel was dried and autoradiographed. The polypeptides obtained from the serum specimens were transferred electrophoretically to nitrocellulose paper for Western blotting. The high-affinity binding of '25I-Meg-CSF to AM-IgG precipitated by protein A was determined by subtraction of low-affinity binding obtained by the addition of 300-fold excess unlabeled Meg-CSF.
Western blotting. Western blotting was performed according to the method of Towbin et al. (17) using a Trans-Blot cell (Bio-Rad Laboratories). Polypeptide transfer to nitrocellulose paper (15 X 15 cm) was accomplished immediately after the termination of electrophoresis and incubated with AM-IgG for 2 h, then reacted with "25I-protein A (10-106 cpm; Amersham Corp., Arlington Heights, IL; specific activity, 30 ,uCi/mg; concentration, 100 MuCi/ml). Bound 1251 was detected by autoradiography using X-Omat AR film (Eastman Kodak Co., Rochester, NY) and Dupont Lightening (E. I. Du Pont de Nemours & Co., Inc., Wilmington, DE) plus intensifying screens at -70°C for 24-48 h.
Megakaryocyte colony stimulatingfactor assay. Meg-CSF was assayed in plasma clot cultures containing 5 x l0s bone marrow mononuclear cells (18) . The bone marrow aspirate was diluted 1:1 with alpha-medium minus nucleosides (Gibco, Grand Island, NY), containing preservativefree sodium heparin at 20 U/ml and layered over an equal volume of Ficoll-Paque (specific gravity, 1.077 g/cm3; Pharmacia Fine Chemicals, Piscataway, NJ). Density centrifugation was performed at 500 g for 25 min at 4°C in a Beckman model TJ-6R centrifuge (Beckman Instruments, Inc.). The interface mononuclear cell layer was collected and washed with alpha-medium minus nucleosides containing 2% fetal calf serum. Mononuclear cells at 5 X lIO cells/ml were cultured in l-ml volumes in 35-mm petri dishes. The plasma clot technique of McLeod et al. (18) was modified by the substitution of heat-inactivated human AB serum for fetal calf serum, and alpha-medium minus nucleosides for NCTC-109 medium and Eagle's minimal essential medium with Hank's balanced salt solution. Samples to be assayed for Meg-CSF activity were diluted in alpha-medium minus nucleosides at several dilutions. The final 1-ml aliquot ofeach culture contained the following supplements: alpha-media minus nucleosides, sodium bicarbonate (1.2%), nonessential amino acids (0.01 mmol/ml), L-glutamine (0.4 mmol/ml), and sodium pyruvate (0.2 mmol/ml). Culture dishes were incubated for 10-12 d (unless otherwise stated) at 37°C in a 100% humidified atmosphere of 5% CO2 in air. Harvesting was performed by in situ fixation with methanol/acetone (1: 3) for 20 min, washing with 0.01 M PBS, pH 7.2, then distilled water, and subsequently air dried. Plasma clots were stored frozen at -20°C until immunofluorescent staining was performed.
Immunofluorescent identifcation ofhuman megakaryocyte colonies.
Whole rabbit anti-PGP antiserum, previously established as a megakaryocyte specific marker (8) , was diluted in PBS (1:200), layered over the fixed plasma clot culture, and incubated for 60 min at room temperature in 100% -humidified air. After washing three times with PBS, the specimens were reincubated for an additional 60 min with fluorescein-conjugated goat anti-rabbit IgG (Meloy Laboratories, Inc., Springfield, VA) diluted in PBS, final concentration, 0.36 mg protein/ml. After being washed with PBS, the specimens were counterstained with 0.125% Evan's Blue for 5 min, washed with distilled water, and mounted in isotonic barbital buffer, pH 8.6, in glycerol (1:3).
Plasma clot cultures were scored in situ in order to enumerate fluorescein positive colonies. The 35-mm petri dishes were inverted and the base area was completely scanned with a fluorescence microscope at 100 X (Zeiss standard microscope 18 with IV FL vertical fluorescent illuminator; Carl Zeiss, Inc., Thornwood, NY). A megakaryocyte colony was defined as a cluster ofthree or more intensely fluorescent cells. Each study was performed in duplicate to quadruplicate. Specific activity of Meg-CSF preparations was calculated from the number of megakaryocyte colonies per milligram protein from the linear portion ofthe dose response curve.
Assayfor other hematopoietic colonies. Both BFU-E and CFU-E derived colony assays were performed in plasma clot cultures as previously described (19) . Human EPO, specific activity, 30-50 U/mg of protein (Toyobo Co., LTD, Osaka, 530 Japan) was used in these studies. Plasma clots were fixed in situ with 5% glutaraldehyde in 0.01 M phosphate buffer (pH, 7.0-7.2). Colony forming unit-erythroid (CFU-E) and burst forming unit-erythroid (BFU-E) derived colonies were harvested after 7 and 12-14 d of incubation, respectively. Cultures were stained with 1% benzidine and hematoxylin as previously described (19) . Maximum growth of CFU-E and BFU-E derived colonies in this modified plasma clot assay system was seen at EPO concentrations of 0.5 and 1.0 IU/ml, respectively.
The colony assay for granulocyte-macrophage colony-forming units (CFU-GM) was carried out according to the method ofFauser and Messner (20) . In brief, marrow mononuclear cells were suspended in 35 mm Lux standard tissue culture dishes, containing a l-ml mixture of Iscove's modified Dulbecco's medium (IMDM; Gibco Laboratories), 0.8% methylcellulose, 30% fetal bovine serum, 10% medium conditioned by leukocytes from patients with hemochromatosis in the presence of 1% phytohemagglutinin-stimulated leukocyte conditioned medium (PHA-LCM), and 5 X 10-5 M 2-mercaptoethanol. Dishes were incubated at 37°C in a humidified atmosphere flushed with 5% CO2 in air. Colonies were scored with an inverted microscope after 13-14 d ofincubation. Clusters of .40 cells, many of which had typical band or segmented polymorphonuclear leukocyte morphology, were defined as CFU-GM derived colonies. The assay for human granulocyte-erythroid-macrophagemegakaryocyte (CFU-GEMM) derived colonies as described by Fauser and Messner (21) was used to assess the effect of growth factors on multipotential colony forming unit cells.
Neutralization test. The ability of the anti-Meg-CSF IgG fraction (AM-IgG, 2.7 mg/ml) to neutralize Meg-CSF activity was assessed using two methods. First, the anti-Meg-CSF IgG fraction (AM-IgG, 2.7 mg/ ml) or the IgG fraction (2.7 mg/ml) of normal rabbit serum was diluted in saline and mixed with an equal volume of either AAS, purified Meg-CSF, PHA-LCM, or a partially purified preparation of human urinary erythropoietin and incubated at 25°C for I h before adding to the cultures.
Control cultures were established with the same stimulus mixed with an equal volume of physiological saline. The ability of these mixtures to promote megakaryocyte, granulocyte-macrophage, or erythroid-derived colony formation by normal human marrow cells was determined using the various assays described above. The number of each type of hematopoietic colony was determined. The second method for assessing the neutralizing ability of the AM-IgG was as follows: AM-IgG and normal rabbit IgG were diluted in saline as above and mixed with an equal volume of AAS and incubated at 25°C for 1 h, followed by an additional incubation at 4°C overnight. The immune complexes that were formed were precipitated by adding 10 mg of protein A-Sepharose swollen in PBS. This mixture was allowed to rotate at 4°C for 2 h and was subsequently centrifuged at 8,000 g for 5 min in a Fisher microfuge (Model 59-A). The ability ofthe supernatants to promote CFU-M derived colony formation by normal marrow cells was determined. In order to further define the specificity ofthe AM-IgG neutralizing activity, we assessed the ability of increasing amounts of purified Meg-CSF to overwhelm the antibody effect. The inhibitory activity of the normal rabbit IgG or the AM-IgG was expressed as the percent of the control number of colonies formed. The titer was expressed as that dilution which caused a 50% reduction in colony numbers.
Statistics. The student t test was performed with a statistical package compatible with an Apple II computer (Apple Computer, Cupertino, CA).
Results
The immunogen used to produce the anti-Meg-CSF antibody was purified from the plasma ofa patient with hypomegakaryocytic thrombocytopenia according to the methods of Hoffman and co-workers (7) . The active Meg-CSF band was cut out and extracted from the preparative SDS-polyacrylamide gel, thus recovering 60-80% of the loaded sample. When 10 Ag of the extracted protein was analyzed with two-dimensional gel electrophoresis, it migrated as a single band and showed no evidence of contamination with other proteins (Fig. 1) .
Both rabbits immunized with purified Meg-CSF produced antisera to Meg-CSF. IgG fractions were purified from preimmune rabbit serum and antiserum obtained from the immunized rabbits. The preparations revealed a single band in the gamma globulin region when purified IgG fractions were examined in SDS-polyacrylamide gel at pH 8.8 . The reactivity of AM-IgG with Meg-CSF was examined by means of immunodiffusion, immunoelectrophoresis, and Western blotting.
As shown in Fig. 2 A, the purified Meg-CSF formed a single precipitin line with the antibody when placed in an immunodiffusion system. As shown in Fig. 2 B, the antibody did not form a precipitin line with TSF, purified from human embryonic kidney cell conditioned media (gift of T. P. McDonald, University of Tennessee, Knoxville, TN), or human urinary EPO (specific activity, 500 U/mg of protein, Alpha-Therapeutics Corp., Los Angeles, CA). However, the antibody did form a single precipitin line with Meg-CSF purified by preparative electrophoresis (Fig. 2 B) and the fraction obtained after high performance liquid chromatography (Fig. 3) , which suggests that the Meg-CSF was immunochemically distinct from both TSF and EPO. The preimmune IgG fraction was run under the same conditions as the immune IgG fraction and at various concen- Using immunoprecipitation and Western blotting techniques ( Fig. 4) , several potential sources of hematopoietic growth factors were also examined for reactivity with the anti Meg-CSF IgG fraction. The AM-IgG formed a precipitin band with AAS, normal human serum, and purified Meg-CSF but not with preparations of TSF or EPO.
In Fig. 5 , the ability of purified AM-IgG fraction to immunoprecipitate iodinated Meg-CSF was examined. The iodinated purified Meg-CSF had a specific activity of 0.45 mCi/,gg of protein. The anti-Meg-CSF IgG fraction efficiently immunoprecipitated the iodinated protein which migrated with an apparent molecular weight of 46,000 on SDS-PAGE analysis. -80% of the labeled protein was maximally precipitated with an AM-IgG concentration of 0.67 mg/ml. Normal rabbit IgG precipitated <1% of the labeled protein and no detectable band on autoradiography at a concentration up to 2 mg/ml (data not shown). The autoradiograph ofthe immune complexes formed with var--~~~~~~~~~~~~iX_ Figure 3 . Immunoelectrophoretogram of purified Meg-CSF. Meg-CSF was obtained from the major peak following purification by reversephase high pressure liquid chromatography. Trough, AM-IgG; antigen well, human Meg-CSF. A single precipitin line was revealed.
AM-IgG (5 Ml of 2.7 mg/ml) was placed in center well. Growth factors of comparable concentrations were placed in the outer wells as follows: 1, purified human Meg-CSF (1.0 Mg); 2, preimmune rabbit IgG (5.0 Ag); 3, TSF (purified from human embryonic kidney cell-conditioned media, 1.0 Mug); 4, and 5, human urinary erythropoietin (sp act, 500 U/mg of protein, Lot No. EHO09TO, 1.0 and 2.0 ,g per well, respectively).
ious dilutions of AM-IgG and iodinated Meg-CSF is shown in Fig. 6 .
Neutralization of Meg-CSF activity present in AAS and purified human Meg-CSF by the AM-IgG fraction is demonstrated in Table I . The AM-IgG at various concentrations was unable to alter the baseline megakaryocyte colony formation that occurs in the absence of added Meg-CSF (data not shown). The AM-IgG was able to neutralize the megakaryocyte colony stimulating activity present in AAS or purified Meg-CSF at a statistically significant level (P < 0.001). At a dilution of 1:256, the AM-IgG resulted in a 55% reduction in megakaryocyte colony formation stimulated by AAS. As shown in Table II , this neutralization effect was overcome by adding increasing amounts of purified Meg-CSF. When the supernatants of AAS from which the Meg-CSF had been immune-precipitated were incubated with protein A Sepharose beads to remove free residual AM-IgG Meg-CSF immune qomplexes, these fractions still were unable to promote megakaryocyte colony formation. Neutralization of the ability of purified Meg-CSF to promote megakaryocyte colony formation occurred up to a 1:1,024 dilution of AM-IgG.
The inability of the anti Meg-CSF IgG fraction to neutralize the effect of EPO in promoting CFU-E and BFU-E derived colony formation is shown in Table III. In addition, treatment with AM-IgG did not influence CFU-GEMM or BFU-E derived colony formation when stimulated by EPO + PHA-LCM. Similar treatments did not influence the ability of PHA-LCM to promote CFU-GM derived colony formation. This lack of effect on in vitro erythropoiesis, granulopoiesis, and on the formation of mixed colonies suggests that AM-IgG does not act by a direct toxic action on the colony-forming cells or by reacting with nutrients in the culture medium. Therefore, these experiments a. substantiate the specificity of the AM-IgG. In this series of experiments and in previously reported studies (4, 8) serial dilutions of Am-IgG were used for each point. The total binding radioactivity (o) was determined from the precipitated immune-complexes that were dissociated and eluted off from protein A Sepharose. Low-affinity binding radioactivity was obtained by adding 300-fold excess of unlabeled Meg-CSF to labeled Meg-CSF (i). Specific, high-affinity binding radioactivity (A&) was calculated by taking the difference between the total and low-affinity binding.
Discussion
Factors that control human thrombopoiesis and megakaryocytopoiesis have not been well characterized. Recently, clonal culture techniques have been developed that allow the quantitation ofhuman megakaryocyte colony forming units (CFU-M) in bone marrow and peripheral blood (8, 22) . A number ofinvestigators have detected factors from a variety of sources that promote megakaryocyte colony formation (23) (24) (25) (26) (27) (28) (29) The iodination, immune precipitation, and subsequent analysis on 10% polyacrylamide gels were done as described in Methods. The gel was dried and exposed to X-Ray film. The position of the indicated standard proteins was determined by Coomassie Blue staining. megakaryocyte colony formation. Additionally, serum, plasma and urine (1, 2) of thrombocytopenic patients have been shown to possess Meg-CSF activity. Meg-CSF not only increases CFU-M cloning efficiency, but also increases the proliferative capacity of individual CFU-M as evidenced by a statistically significant increase in the numbers of cells present per colony (4) . The variations in Meg-CSF levels that have been detected in different disease states suggest that alterations in the production of this regulator are physiologically important (2) .
Purified regulatory molecules and cell populations must be available before we can unravel the complexities of human megakaryocytopoiesis (29, 30) . In the study of erythropoiesis and granulopoiesis, purification of EPO, erythropoietic burst promoting activity, and various subclasses of granulocyte-macrophage colony stimulating factors have provided a better understanding of both granulopoiesis and erythropoiesis (27, [29] [30] [31] [32] [33] [34] . We have recently adopted this approach and have purified human Meg-CSF using a four-step purification scheme (7) . This process has resulied in the isolation of a 46,000-mol-wt glycoprotein that promotes megakaryocyte colony formation. We have now used the purified Meg-CSF to produce an AM-IgG fraction. The present study shows that Meg-CSF purified from hypomegakaryocytic plasma is indeed immunogenic. Immunization of rabbits with this material has resulted in the production of an IgG fraction able to neutralize the ability of AAS as well as purified Meg-CSF to promote megakaryocyte colony formation. Using standard immunological techniques we have attempted to clarify several important questions concerning the regulation of megakaryocytopoiesis. Vainchenker et al. (9) first reported that human serum contains an inhibitor of megakaryocyte colony formation. Messner et al. (26) and Kimura et al. (35) have presented evidence that plasma is superior to serum in its ability to support megakaryocyte colony formation in a methylcellulose assay system. Kimura et al. (35) also showed that the direct addition of intact or frozen-thawed platelets to methylcellulose assays resulted in a decrease in numbers of megakaryocyte colonies formed. Using a plasma clot culture system, we have not been able to detect the superiority ofplateletpoor plasma-derived serum over crude serum or platelet-rich plasma-derived serum in their ability to support megakaryocyte colony formation (Hoffman, R., and E. Bruno, unpublished observations). The work demonstrating differences in the ability ofplasma and serum to support colony growth have led Kimura and co-workers (35) to suggest that the enhanced ability of AAS to promote CFU-M cloning efficiency might merely be due to these sera containing less platelet-derived inhibitory activity than serum from patients with elevated platelet counts. This hypothesis would seem to be highly unlikely in light of our observation that the anti-Meg-CSF antibody can neutralize the activity of AAS to promote CFU-M cloning efficiency. In addition, the formation of a precipitin band between the anti Meg-CSF IgG fraction and AAS and normal serum also suggests the presence of an immunologically distinct macromolecule in these specimens which share a common polypeptide segment.
Since a number ofinvestigators have reported that EPO and TSF can support megakaryocyte colony formation (18, 27, 28) , it was important to determine the relationship between TSF, EPO, and purified Meg-CSF. We have previously reported that neither TSF nor EPO increases megakaryocyte colony formation (4) . The inability of the anti-Meg-CSF antibody to react with either TSF or EPO suggests that these factors are at least immunologically unrelated molecules. The possibility does exist that at high concentrations of TSF or EPO that are artificially created in clonal assay systems, either of these factors might influence in vitro megakaryocyte colony formation. It would appear unlikely, however, that either TSF or EPO are primary physiological regulators of megakaryocytopoiesis at the level of the CFU-M.
Interleukin 3 (IL-3) is a lymphokine first defined by its capacity to induce 20-a-hydroxysteroid dehydrogenase (20-a-SDH) in spleen cells ofneonatal nude mice (37) . IL-3 has been purified to homogeneity and its responsible gene cloned (37, 38) . has been shown to possess a number of hematopoietic growth factor-like activities (39). Quesenberry and co-workers (40) have presented data that suggest that IL-3 is a potent stimulator of in vitro murine megakaryocyte colony formation. IL-3 appears to represent the marrow cell-line inducing activity present in media conditioned by the murine myelomonocyte cell line WEHI-3 (41) . WEHI-3 cell conditioned medium has also been used as a source of murine Meg-CSF. Recently, Williams and co-workers (42) have shown that the Meg-CSF in WEHI-3 cell conditioned medium was identical to IL-3. The relationship of human Meg-CSF to IL-3 is unknown. Unfortunately, there is no purified human molecule equivalent to murine IL-3 available with which to define this relationship. However, this issue was explored using the anti-Meg-CSF IgG fraction. Crude PHA-LCM prepared from human mononuclear cells possesses many IL-3like activities (43) . The PHA-LCM had burst promoting activity, granulocyte-macrophage colony stimulating activity, and multipotential colony stimulating activity. The AM-IgG fraction was able to neutralize the ability of AAS and purified Meg-CSF to stimulate megakaryocyte colony formation but did not alter the ability of PHA-LCM to support CFU-GM, CFU-GEMM, or BFU-E derived colony formation. In addition, using Western blotting, we were unable to detect any Meg-CSF in several different batches ofPHA-LCM (data not shown). These data suggest that the purified Meg-CSF is immunologically distinct from the IL-3-like activity present in PHA-LCM. The detection of Meg-CSF in normal serum using AM-IgG as an immunological probe was a surprising finding. This data would suggest that detectable levels of this factor are present in most individuals in order to maintain baseline megakaryocytopoiesis and thrombopoiesis. These findings are consistent with previous data published by our laboratory, which suggest that Meg-CSF is required in vitro at higher concentrations than previously recognized for other hematological growth factors (7, 43, 44) . The reasons for this discrepancy are unknown to us, but could indicate the unique properties of Meg-CSF.
The data presented in this report clearly demonstrate the presence of Meg-CSF in AAS and normal serum. This factor appears to play a pivotal role in the regulation of megakaryocytopoiesis. Although we have been unable to detect a serum inhibitor of megakaryocyte colony formation, our results do not exclude the presence of such a factor. The possibility arises that the methylcellulose assay system might be more sensitive in the detection of such inhibitors than the plasma clot culture system. Our present studies, however, do clearly define the presence of Meg-CSF-like activity in human serum. Whether the effect of this factor can be blunted by inhibitory molecules originating in platelets is a question that we are now approaching, using a better defined serum-free culture system.
